Shop the Archives and get your next eBook for just 14.99! Stock up today >>

Resistance to Targeted Anti-Cancer Therapeutics

Resistance to Ibritumomab in Lymphoma

Editors: Hosono, Makoto, Chatal, Jean-François (Eds.)

    • This book features chapters written by internationally known experts in the field
    • This book will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects and medical physics that deals with radiation dosimetry
    • This book will provide future prospects for overcoming resistance and enhancing the efficacy of Ibritumomab
おすすめポイントをすべて見る

書籍の購入

イーブック 101,14 €
価格の適用国: Japan (小計)
  • ISBN 978-3-319-78238-6
  • ウォーターマーク付、 DRMフリー
  • ファイル形式: EPUB, PDF
  • どの電子書籍リーダーからでもすぐにお読みいただけます。
  • ご購入後、すぐにダウンロードしていただけます。
ハードカバー 119,99 €
価格の適用国: Japan (小計)
  • ISBN 978-3-319-78237-9
  • 個人のお客様には、世界中どこでも配送料無料でお届けします。
  • Usually dispatched within 3 to 5 business days.
この書籍について

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

著者について

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 


Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Table of contents (10 chapters)

  • Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma

    Choi, Ilseung (et al.)

    Pages 1-8

  • Biology and Pathology of B-Cell Lymphoma

    Tatsumi, Yoichi

    Pages 9-31

  • Resistance to Y-90 Ibritumomab Tiuxetan Therapy

    Abe, Koichiro

    Pages 33-57

  • Features of Ibritumomab as Radionuclide Therapy

    Hosono, Makoto

    Pages 59-66

  • Radiological Evaluation of Response and Resistance of Ibritumomab

    Ishimori, Takayoshi (et al.)

    Pages 67-77

    Preview Buy Chapter 26,95 €

書籍の購入

イーブック 101,14 €
価格の適用国: Japan (小計)
  • ISBN 978-3-319-78238-6
  • ウォーターマーク付、 DRMフリー
  • ファイル形式: EPUB, PDF
  • どの電子書籍リーダーからでもすぐにお読みいただけます。
  • ご購入後、すぐにダウンロードしていただけます。
ハードカバー 119,99 €
価格の適用国: Japan (小計)
  • ISBN 978-3-319-78237-9
  • 個人のお客様には、世界中どこでも配送料無料でお届けします。
  • Usually dispatched within 3 to 5 business days.
Loading...

あなたへのおすすめ

Loading...

書誌情報

Bibliographic Information
Book Title
Resistance to Ibritumomab in Lymphoma
Editors
  • Makoto Hosono
  • Jean-François Chatal
Series Title
Resistance to Targeted Anti-Cancer Therapeutics
Series Volume
18
Copyright
2018
Publisher
Springer International Publishing
Copyright Holder
Springer International Publishing AG, part of Springer Nature
イーブック ISBN
978-3-319-78238-6
DOI
10.1007/978-3-319-78238-6
ハードカバー ISBN
978-3-319-78237-9
Series ISSN
2196-5501
Edition Number
1
Number of Pages
XIII, 158
Number of Illustrations and Tables
4 b/w illustrations, 14 illustrations in colour
Topics